How to use natriuretic peptide levels for diagnosis and prognosis

European Heart Journal

Volumn 20, Issue 19, 1999, Pages 1374-1375

  Struthers, A D ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NATRIURETIC FACTOR;

EDITORIAL; HEART LEFT VENTRICLE FAILURE; HUMAN; PRIORITY JOURNAL; PROGNOSIS;

ALGORITHMS; ATRIAL NATRIURETIC FACTOR; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HUMANS; PROGNOSIS; VENTRICULAR FUNCTION, LEFT;

EID: 0032851020     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1771     Document Type: Editorial

References (4)

1. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for ACE inhibition after myocardial infarction. Lancet 1993; 341: 1109-13.
2. Pinamonti B, Di Leonarda A, Sinaga G, Camerini F. Restrictive LV filling pattern in dilated cardiomyopathy assessed by doppler echo: clinical, echocardiographic and haemodynamic correlation and prognostic implications. J Am Coll Cardiol 1993; 22: 808-15.
3. Fruhwald FM, Fahrleitner A, Watzinger N et al. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J 1999; 20: 1415-23.
4. Yu CM, Sanderson JE, Sham IOL et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996; 17: 1694-1702.